{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:34:12Z","timestamp":1790094852240,"version":"4.0.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.jaad.2019.03.049","type":"journal-article","created":{"date-parts":[[2019,3,25]],"date-time":"2019-03-25T18:52:28Z","timestamp":1553539948000},"page":"179-186","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":72,"title":["Rituximab therapy in patients with bullous pemphigoid: A retrospective study of 20 patients"],"prefix":"10.1016","volume":"81","author":[{"given":"Maxim","family":"Polansky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Eisenstadt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taryn","family":"DeGrazia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiwen","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2019.03.049_bib1","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/j.1365-2133.2005.06662.x","article-title":"Annual incidence and mortality of bullous pemphigoid in the Grampian Region of North-East Scotland","volume":"153","author":"Gudi","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2019.03.049_bib2","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0190-9622(99)70061-7","article-title":"Increased risk of bullous pemphigoid in male and very old patients: a population-based study on incidence","volume":"41","author":"Jung","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2019.03.049_bib3","first-page":"317","article-title":"Bullous pemphigoid in Liguria: a 2-year survey","volume":"15","author":"Cozzani","year":"2001","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2019.03.049_bib4","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1038\/jid.2012.35","article-title":"Incidence and mortality of bullous pemphigoid in France","volume":"132","author":"Joly","year":"2012","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2019.03.049_bib5","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/archderm.1995.01690130050009","article-title":"Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions. Bullous Diseases French Study Group","volume":"131","author":"Bernard","year":"1995","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2019.03.049_bib6","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/bjd.14821","article-title":"Hospitalization, inpatient burden and comorbidities associated with bullous pemphigoid in the U.S.A","volume":"176","author":"Ren","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2019.03.049_bib7","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/jid.2010.301","article-title":"Risk factors for bullous pemphigoid in the elderly: a prospective case-control study","volume":"131","author":"Bastuji-Garin","year":"2011","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jaad.2019.03.049_bib8","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/j.jaad.2014.07.052","article-title":"A population-based study of the association between bullous pemphigoid and neurologic disorders","volume":"71","author":"Brick","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2019.03.049_bib9","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1001\/archdermatol.2010.322","article-title":"The association of bullous pemphigoid with cerebrovascular disease and dementia: a case-control study","volume":"146","author":"Taghipour","year":"2010","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2019.03.049_bib10","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1111\/j.0022-202X.2004.22504.x","article-title":"Mortality rate of bullous pemphigoid in a US medical center","volume":"122","author":"Colbert","year":"2004","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2019.03.049_bib11","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/j.0022-202X.2005.23628.x","article-title":"Sepsis associated with dermatologic hospitalization is not the cause of high mortality of bullous pemphigoid in Europe","volume":"124","author":"Garcia-Doval","year":"2005","journal-title":"J Invest Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2019.03.049_bib12","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1111\/bjd.15649","article-title":"An open, multicenter, randomized clinical study in patients with bullous pemphigoid comparing methylprednisolone and azathioprine with methylprednisolone and dapsone","volume":"177","author":"Sticherling","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2019.03.049_bib13","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S0140-6736(17)30560-3","article-title":"Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial","volume":"389","author":"Williams","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2019.03.049_bib14","first-page":"CD002292","article-title":"Interventions for bullous pemphigoid","volume":"10","author":"Kirtschig","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaad.2019.03.049_bib15","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/bjd.13633","article-title":"First-line combination therapy with rRituximab and corticosteroids provides a high complete remission rate in moderate-to-severe bullous pemphigoid","volume":"173","author":"Cho","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2019.03.049_bib16","doi-asserted-by":"crossref","first-page":"928","DOI":"10.2340\/00015555-2116","article-title":"Efficacy of rituximab for pemphigus: a systematic review and meta-analysis of different regimens","volume":"95","author":"Wang","year":"2015","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2019.03.049_bib17","first-page":"672","article-title":"Treatment of bullous pemphigoid with rituximab: critical analysis of the current literature","volume":"12","author":"Shetty","year":"2013","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2019.03.049_bib18","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.jaad.2015.01.029","article-title":"Infectious complications in bullous pemphigoid: an analysis of risk factors","volume":"72","author":"Phoon","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2019.03.049_bib19","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1001\/archderm.134.9.1075","article-title":"Evaluation of clinical criteria for diagnosis of bullous pemphigoid","volume":"134","author":"Vaillant","year":"1998","journal-title":"Arch Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2019.03.049_bib20","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1001\/jamadermatol.2013.5757","article-title":"Clinical and immunologic factors associated with bullous pemphigoid relapse during the first year of treatment: a multicenter, prospective study","volume":"150","author":"Fichel","year":"2014","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2019.03.049_bib21","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jaad.2011.06.032","article-title":"Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts","volume":"66","author":"Murrell","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2019.03.049_bib22","unstructured":"Nickleach D, Liu Y, Shrewsberry A, et\u00a0al. SAS\u00ae Macros to conduct common biostatistical analyses and generate reports. SESUG 2013: proceedings of the SouthEast SAS User Group Conference. 2013. Available from: http:\/\/analytics.ncsu.edu\/sesug\/2013\/PO-05.pdf. Accessed September 1, 2018."},{"key":"10.1016\/j.jaad.2019.03.049_bib23","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1177\/1094428104263672","article-title":"Using generalized estimating equations for longitudinal data analysis","volume":"7","author":"Ballinger","year":"2004","journal-title":"Org Res Methods"},{"issue":"10083","key":"10.1016\/j.jaad.2019.03.049_bib24","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial","volume":"389","author":"Joly","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2019.03.049_bib26","series-title":"Key statistics for prostate cancer","year":"2018"},{"key":"10.1016\/j.jaad.2019.03.049_bib27","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1136\/annrheumdis-2012-201956","article-title":"Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients","volume":"72","author":"Van Vollenhoven","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2019.03.049_bib28","doi-asserted-by":"crossref","first-page":"45","DOI":"10.5021\/ad.2012.24.1.45","article-title":"Usefulness of enzyme-linked immunosorbent assay using recombinant BP180 and BP230 for serodiagnosis and monitoring disease activity of bullous pemphigoid","volume":"24","author":"Lee","year":"2012","journal-title":"Ann Dermatol"},{"key":"10.1016\/j.jaad.2019.03.049_bib29","first-page":"145e9","article-title":"Correlation of clinical severity and ELISA indices for the NC16A domain of BP180 measured using BP180 ELISA kit in bullous pemphigoid","volume":"37","author":"Tsuji-Abe","year":"2005","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.jaad.2019.03.049_bib30","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1111\/bjd.13717","article-title":"Management of bullous pemphigoid: the European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology","volume":"172","author":"Feliciani","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2019.03.049_bib31","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1001\/archdermatol.2009.53","article-title":"Risk factors for relapse in patients with bullous pemphigoid in clinical remission","volume":"145","author":"Bernard","year":"2009","journal-title":"Arch Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2019.03.049_bib32","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2340\/0001555564243246","article-title":"Serum IgE levels in patients with bullous pemphigoid and its correlation to the activity of the disease and anti-basement membrane zone antibodies","volume":"64","author":"Asbrink","year":"1984","journal-title":"Acta Derm Venereol"},{"issue":"2","key":"10.1016\/j.jaad.2019.03.049_bib33","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1365-2133.1994.tb02909.x","article-title":"Bullous pemphigoid in a 19-year-old woman. a case with unusual target antigens","volume":"130","author":"Mori","year":"1994","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2019.03.049_bib34","first-page":"69","article-title":"Serum levels of IgE-antibodies against the immunodominant BP180-NC16A domain correlate with the disease activity of patients with bullous pemphigoid","volume":"13","author":"Van Beek","year":"2015","journal-title":"J Dtsch Dermatol Ges"},{"issue":"2","key":"10.1016\/j.jaad.2019.03.049_bib35","first-page":"186","article-title":"Exploring mechanisms of IgE-mediated autoimmunity through the lens of bullous pemphigoid","volume":"151","author":"Messingham","year":"2016","journal-title":"G Ital Dermatol Venereol"},{"issue":"5","key":"10.1016\/j.jaad.2019.03.049_bib36","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/S0190-9622(83)70073-3","article-title":"Bullous pemphigoid: a cause of peripheral blood eosinophilia","volume":"8","author":"Bushkell","year":"1983","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2019.03.049_bib37","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1111\/bjd.16679","article-title":"Peripheral eosinophilia in bullous pemphigoid: prevalence and influence on the clinical manifestation","volume":"179","author":"Kridin","year":"2018","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2019.03.049_bib38","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/cei.12481","article-title":"Usefulness of monitoring of B cell depletion in rituximab-treated rheumatoid arthritis patients in order to predict clinical relapse: a prospective observational study","volume":"180","author":"Trouvin","year":"2015","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaad.2019.03.049_bib39","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.jaad.2017.07.012","article-title":"Developing biomarkers for predicting clinical relapse in pemphigus patients treated with rituximab","volume":"77","author":"Albers","year":"2017","journal-title":"J Am Acad Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962219304670?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962219304670?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:51:40Z","timestamp":1759272700000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962219304670"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S0190962219304670"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2019.03.049","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rituximab therapy in patients with bullous pemphigoid: A retrospective study of 20 patients","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2019.03.049","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}